The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.

Bisphosphonates are effective in the management of bone disease in patients with multiple myeloma and recent reports have suggested that they may also have an anti-tumour activity. In support of this, we have previously demonstrated that bisphosphonates can induce myeloma cell apoptosis in vitro; ho...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Shipman, C, Vanderkerken, K, Rogers, M, Lippitt, J, Asosingh, K, Hughes, D, Van Camp, B, Russell, R, Croucher, P
Format:	Journal article
Sprache:	English
Veröffentlicht:	2000

Ähnliche Einträge

Bisphosphonates--mechanisms of action in multiple myeloma.
von: Shipman, C, et al.
Veröffentlicht: (2000)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
von: Croucher, P, et al.
Veröffentlicht: (2003)

Bisphosphonates and in vivo models of multiple myeloma - Reply
von: Shipman, C, et al.
Veröffentlicht: (2001)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
von: Vanderkerken, K, et al.
Veröffentlicht: (2003)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
von: Croucher, P, et al.
Veröffentlicht: (2001)

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
von: Shipman, C, et al.
Veröffentlicht: (1997)

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
von: Shipman, C, et al.
Veröffentlicht: (1998)

Anti-tumour activity of bisphosphonates in human myeloma cells.
von: Shipman, C, et al.
Veröffentlicht: (1998)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
von: Croucher, P, et al.
Veröffentlicht: (2000)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
von: Croucher, P, et al.
Veröffentlicht: (2001)

Osteoprotegerin and the development of myeloma bone disease
von: Croucher, P, et al.
Veröffentlicht: (2004)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
von: Croucher, P, et al.
Veröffentlicht: (2002)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
von: Croucher, P, et al.
Veröffentlicht: (2001)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
von: Croucher, P, et al.
Veröffentlicht: (2002)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
von: Shipman, C, et al.
Veröffentlicht: (2000)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
von: Shipman, C, et al.
Veröffentlicht: (2002)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
von: Mueller, G, et al.
Veröffentlicht: (2004)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
von: Mueller, G, et al.
Veröffentlicht: (2004)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
von: Shipman, C, et al.
Veröffentlicht: (2002)

Nitrogen-containing bisphosphonates induce apoptosis in human bone marrow-derived myeloma cells in vitro by inhibiting protein prenylation.
von: Gordon, S, et al.
Veröffentlicht: (1999)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
von: Edwards, C, et al.
Veröffentlicht: (2007)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
von: De Leenheer, E, et al.
Veröffentlicht: (2004)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
von: Shipman, C, et al.
Veröffentlicht: (2000)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
von: De Leenheer, E, et al.
Veröffentlicht: (2002)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
von: Locklin, R, et al.
Veröffentlicht: (2005)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
von: Croucher, P, et al.
Veröffentlicht: (2003)

The bisphosphonate-ester apornine does not act by inhibiting protein prenylation, but enhances the effects of lovastatin on myeloma cells
von: Roelofs, A, et al.
Veröffentlicht: (2006)

Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
von: Richard Derman, et al.
Veröffentlicht: (2009-09-01)

Osteoblasts protect multiple myeloma cells from T-cell-induced apoptosis
von: Locklin, R, et al.
Veröffentlicht: (2007)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
von: Liesbeth Bieghs, et al.
Veröffentlicht: (2010-01-01)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
von: Shipman, C, et al.
Veröffentlicht: (2002)

The Effectiveness of Zoledronic Acid and Ibandronic Acid in Delaying Skeletal-Related Events in Multiple Myeloma in Indonesia
von: Nutrisia Aquariushinta Sayuti, et al.
Veröffentlicht: (2020-09-01)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
von: Shipman, C, et al.
Veröffentlicht: (2003)

Administration of bisphosphonate (ibandronate) impedes molar tooth movement in rabbits: A radiographic assessment
von: V Venkataramana, et al.
Veröffentlicht: (2014-01-01)

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
von: Clive Henry Buckle, et al.
Veröffentlicht: (2012-01-01)

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
von: Jagdev, S, et al.
Veröffentlicht: (2001)

NE10790, a phosphonocarboxylate analogue of risedronate, induces human myeloma cell apoptosis in vitro
von: Roelofs, A, et al.
Veröffentlicht: (2004)

Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment.
von: Locklin, R, et al.
Veröffentlicht: (2007)

P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA
von: Maria Nieves Lopez Muñoz, et al.
Veröffentlicht: (2023-08-01)

The pharmacology of bisphosphonates and new insights into their mechanisms of action.
von: Russell, R, et al.
Veröffentlicht: (1999)